Two Kidney Week 2026 analyses tie SGLT2 inhibitors to kidney, CV, and survival gains in T2D, yet over half of patients with diabetic CKD receive neither.
|Articles|August 16, 2021
Pharmacy Times: Week of August 16 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with Douglas Hoey, CEO of the National Community Pharmacists Association, about his recent appointment as president of the World Pharmacy Council and how the role, opportunities, and issues facing community pharmacies internationally compare to the experience of community pharmacists in the United States.
- An article that provides guidance on the use of basal insulin (BI) and insulin pens to enable pharmacists to answer questions regarding the safe and effective use of BI for the management of diabetes.
- A pharmacy quiz on treatments for diabetes.
Advertisement
Related to this article
The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
A current pharmacy resident provides insights on how pharmacy students can manage the transition from student to resident.
Pharmacy performance measures should recognize clinical interventions, patient counseling, prescriber collaboration, and outcomes—not prescription volume alone.
CMS’s GLP-1 Bridge demo bypasses Part D to cover select obesity drugs, with a $50 monthly copay, PA workflow, and strict eligibility through 2027.
Advertisement
Advertisement
Trending on Pharmacy Times
1
SGLT2 Inhibitors Benefit Frail Adults With T2D, Remain Underused
2
CKM Syndrome Stage Linked to CKD Odds, But Primary Care Hurdles Remain
3
Beyond Prescription Volume: Measuring the Pharmacist’s Value
4
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
5